Eli Lilly Q2 2026 earnings rose 48% to $23.0 billion, driven by Mounjaro and Zepbound demand, as the company raised full-year revenue and EPS guidance and advanced its obesity, oncology, and immunology pipeline through regulatory wins and four completed acquisitions.
Biocon Limited posted a 10% YoY rise in Q1 FY27 consolidated revenue to Rs 4,336 crore, powered by 17% biopharma growth, a 349% jump in net profit, and continued biosimilar launches across the US and Canada.
Pfizer Q2 2026 Earnings report $15.03B in revenue, fueled by an 18% operational surge in non-COVID biopharmaceuticals including Padcev and Vyndaqel.
Merck posted $16.6 billion in Q2 2026 sales as LIPFENDRA won FDA approval and KEYTRUDA QLEX gained traction, even as a Terns acquisition charge drove a GAAP loss.
AbbVie’s Q2 2026 earnings show $16.99 billion in net revenues (+10.2%), record Skyrizi and Rinvoq growth, a $10.9 billion Apogee Therapeutics acquisition, and updated full-year adjusted EPS guidance.
Sun Pharma’s Q1FY27 results show consolidated sales up 10.1% to Rs. 151,836 million, net profit at Rs. 28,948 million, and 16% growth in India Formulations, as the Organon acquisition clears a key shareholder milestone ahead of an early-2027 close.
Amgen data breach headlines have put the biotechnology giant at the center of the healthcare industry’s escalating cybersecurity crisis. Amgen Inc. disclosed on July 31, [Read More…]
Novo Nordisk has released headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating monthly subcutaneous ziltivekimab in patients with ASCVD, CKD, and elevated systemic inflammation.
Genentech and Roche have filed a new patent-infringement lawsuit against Biocon in New Jersey federal court, alleging Biocon’s proposed pertuzumab biosimilar infringes patents covering Perjeta, Roche’s blockbuster HER2-positive breast-cancer treatment, the second major U.S. action against Biocon over the same product in 2026.
Sanofi posted 17.8% Q2 2026 sales growth at constant exchange rates, driven by Dupixent’s record €5.2 billion quarter and a 48.3% jump in pharma launches, prompting an upgraded full-year outlook.
